Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Ye-xiong X. Li

State Key Laboratory Of Molecular Oncology And Department Of Radiation Oncology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
State Key Laboratory Of Molecular Oncology And Department Of Radiation Oncology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Ye-xiong Li practices in Beijing, China. Li is rated as an Experienced expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Their top areas of expertise are Breast Cancer, Mediastinal Tumor, Nasopharyngeal Carcinoma, Mastectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 252 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Locations

State Key Laboratory Of Molecular Oncology And Department Of Radiation Oncology, Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, China
Other Locations
Qingdao, 266000, China
Hefei, 230026, China
Guiyang, 550004, China
Key Laboratory Of Advanced Technologies Of Materials, Chengdu, 610031, China
Jinan, China
Shenzhen, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

249 Total Publications

Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer.
Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer.
Journal: Science advances
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile